Dr Samra Turajlic
Consultant Medical Oncologist
The Royal Marsden
Dr Samra Turajlic completed her undergraduate studies at Oxford University and her clinical training at UCL medical school. She gained a PhD in 2013 from University of London (ICR) in the field of melanoma genetics and targeted therapy resistance. In 2014 she was awarded a CRUK Clinician Scientist Fellowship to study cancer evolution at the Francis Crick Institute (FCI). She completed her training in medical oncology in 2015 and joined the Skin and Urology Units at RMH as a Consultant Medical Oncologist.
She divides her time between the clinic and the Translational Cancer Therapeutics laboratory at the FCI. She is the Chief Clinical Investigator of translational studies into melanoma and kidney cancer. Her main research goal is to improve our understanding of the biology of kidney cancer and melanoma and the reasons for treatment success and failure.
Her clinical research interest is in validating novel targets and therapies for these diseases.
She has received funding grants from Harry J Lloyd Trust, CRUK, RMH-ICR BRC and the Rosetrees Trust.
- kidney cancer
- novel therapies in melanoma and kidney cancer
- cancer research: biology of kidney cancer and melanoma and the mechanisms of treatment resistance